Pre-made Nivatrotamab benchmark antibody ( Bispecific Mixed mAb and scFv, anti-GD2;CD3E therapeutic antibody, Anti-T3E/TCRE/IMD18/CD3epsilon Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Nivatrotamab biosimilar, Bispecific Mixed mAb and scFv, Anti-GD2;CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Nivatrotamab, a humanized bispecific anti-GD2 antibody, is currently in Phase 1 clinical development in collaboration with Memorial Sloan Kettering Cancer Center (¡°MSK¡±) in patients with relapsed/refractory neuroblastoma, as well as high grade osteosarcoma and other GD2(+) solid tumors, where patients have relapsed or refractory disease that is resistant to standard therapy.
| Products Name (INN Index) | Pre-Made Nivatrotamab biosimilar, Bispecific Mixed mAb and scFv, Anti-GD2;CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody |
|---|---|
| INN Name | Nivatrotamab |
| Target | GD2,CD3E |
| Format | Bispecific Mixed mAb and scFv |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1;na |
| VD LC | Kappa,Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2020 |
| Year Recommended | NA |
| Companies | Memorial Sloan-Kettering Cancer Center |
| Conditions Approved | NA |
| Conditions Active | Neuroblastoma |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | GD2,CD3E |
| Package |
